WO2007100590A3 - Methods for treating cellulite - Google Patents

Methods for treating cellulite Download PDF

Info

Publication number
WO2007100590A3
WO2007100590A3 PCT/US2007/004549 US2007004549W WO2007100590A3 WO 2007100590 A3 WO2007100590 A3 WO 2007100590A3 US 2007004549 W US2007004549 W US 2007004549W WO 2007100590 A3 WO2007100590 A3 WO 2007100590A3
Authority
WO
WIPO (PCT)
Prior art keywords
cellulite
methods
skin
relates
collagenase
Prior art date
Application number
PCT/US2007/004549
Other languages
French (fr)
Other versions
WO2007100590A2 (en
Inventor
Marie A Badalamente
Original Assignee
Auxilium Pharmaceuticals Inc
Marie A Badalamente
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auxilium Pharmaceuticals Inc, Marie A Badalamente filed Critical Auxilium Pharmaceuticals Inc
Publication of WO2007100590A2 publication Critical patent/WO2007100590A2/en
Publication of WO2007100590A3 publication Critical patent/WO2007100590A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenous septa network in the skin which comprises cellulite. As such, the invention relates to methods of treating cellulite in a patient in need of such treatment comprising injecting or otherwise delivering the effective amount of purified collagenase to the collagenous septa network of cellulite in the skin. The invention also relates to the use of collagenase in the manufacture of a medicament to treat cetlulite of the skin.
PCT/US2007/004549 2006-02-22 2007-02-20 Methods for treating cellulite WO2007100590A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US60/775,690 2006-02-22

Publications (2)

Publication Number Publication Date
WO2007100590A2 WO2007100590A2 (en) 2007-09-07
WO2007100590A3 true WO2007100590A3 (en) 2008-10-09

Family

ID=38459534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004549 WO2007100590A2 (en) 2006-02-22 2007-02-20 Methods for treating cellulite

Country Status (3)

Country Link
CN (1) CN101405023A (en)
WO (1) WO2007100590A2 (en)
ZA (1) ZA200807221B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012325941A1 (en) * 2011-10-21 2014-05-15 Auxilium International Holdings, Inc. Method of treating or reducing EFP
PT2802652T (en) 2012-01-12 2019-09-10 Endo Global Ventures Clostridium histolyticum enzyme
ES2426017B1 (en) * 2012-03-29 2014-09-17 Proteos Biotech S.L. Microemulsion comprising collagenase and uses
WO2014038097A1 (en) * 2012-09-07 2014-03-13 Shiseido Company, Ltd. Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator
CN115969318A (en) 2017-03-01 2023-04-18 恩多风投有限公司 Device and method for evaluating and treating cellulite
AU2018244426B2 (en) 2017-03-28 2024-09-19 Endo Ventures Limited Improved method of producing collagenase
JP2022502478A (en) * 2018-09-18 2022-01-11 エンド グローバル エステティックス リミテッド Compositions and Methods for Treating Cellulite

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US6335388B1 (en) * 1997-10-03 2002-01-01 Lavipharm Laboratories Inc. Prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6358539B1 (en) * 1999-08-20 2002-03-19 Howard Murad Pharmaceutical compositions for reducing the appearance of cellulite

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US6335388B1 (en) * 1997-10-03 2002-01-01 Lavipharm Laboratories Inc. Prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6358539B1 (en) * 1999-08-20 2002-03-19 Howard Murad Pharmaceutical compositions for reducing the appearance of cellulite

Also Published As

Publication number Publication date
CN101405023A (en) 2009-04-08
WO2007100590A2 (en) 2007-09-07
ZA200807221B (en) 2009-07-29

Similar Documents

Publication Publication Date Title
WO2007100675A3 (en) Collagenase for treating cellulite
WO2006078870A3 (en) Methods for treating adhesive capsulitis
MX2009005527A (en) Methods for treating hypercholesterolemia.
WO2005082339A3 (en) Medicaments and methods for treating headache
NZ588648A (en) Suture line administration technique using botulinum toxins
BRPI0905073A2 (en) Implantable drug depot to reduce, prevent or treat pain in a patient in need of such treatment and method for treating acute pain.
WO2009148605A3 (en) Methods for treating hypercholesterolemia
WO2007100590A3 (en) Methods for treating cellulite
IL171607A (en) Use of a botulinum toxin for the preparation of a medicament for treating sinus headache
BRPI0904955A2 (en) Implantable drug depot to reduce, prevent or treat pain in a patient in need of such treatment and methods for treating acute pain and for making an implantable drug depot.
WO2007029249A3 (en) Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2012062925A3 (en) Compounds and methods for treating pain
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2011041478A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
ATE525084T1 (en) USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR THE TREATMENT OF PAIN RESULTING FROM THERAPEUTIC TREATMENTS FOR THE AIDS VIRUS
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2009130600A3 (en) Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
WO2008008772A3 (en) Methods for treating and limiting fibrotic disorders and keloids

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07751318

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07751318

Country of ref document: EP

Kind code of ref document: A2